前列腺癌组织CHK2和Rsf1蛋白表达及其与临床病理和预后的关系  

Expression of CHK2,Rsf1 in Prostate Cancer Tissues and Its correlation with Clinicopathology and prognosis

作　　者：程蔚蔚 孙硕彤[1] 邓青[1] 徐鹏育 田笑笑[1] CHENG Weiwei;SUN Shuotong;DENG Qing;XU Pengyu;TIAN Xiaoxiao(Department of Pathology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan 471000,China)

机构地区：[1]河南科技大学第一附属医院病理科,河南洛阳471000

出　　处：《实验与检验医学》2021年第6期1375-1378,共4页Experimental and Laboratory Medicine

基　　金：河南省洛阳市2020年度医疗卫生领域指导性科技计划项目,编号2030005A。

摘　　要：目的探讨前列腺癌组织细胞周期检测点激酶2(cell cycle checkpoint kinase 2,CHK2)、染色质重染色质重塑因子-1(remodeling and spacing factor 1,Rsf1)表达水平的变化及临床意义。方法选取2016年1月至2017年12月在我院治疗的前列腺癌患者121例为观察组,另选取同期行手术治疗的良性前列腺增生患者148例为对照组,采用免疫组化法检测前列腺癌组织、良性增生组织中CHK2、Rsf1表达情况。结果观察组CHK2低表达、Rsf1高表达比例明显高于对照组(P<0.001);观察组中,PSA>20 ug/L的患者CHK2低表达、Rsf1高表达比例明显高于PSA≤20 ug/L的患者,III~IV期患者CHK2低表达、Rsf1高表达比例明显高于I~II期患者,Gleason评分≥8分患者CHK2低表达、Rsf1高表达比例明显高于Gleason评分<8分患者,淋巴结转移患者CHK2低表达、Rsf1高表达比例明显高于无淋巴结转移患者(P<0.05);CHK2高表达患者3年总生存率(56.52%)低于CHK2低表达患者(77.55%),Rsf1高表达患者总生存率(82.35%)高于Rsf1低表达患者(62.26%)(P<0.05);Gleason评分≥8分(HR=2.735,95%CI:1.582~3.953)、淋巴结转移(HR=1.942,95%CI:1.492~3.285)以及CHK2低表达(HR=1.628,95%CI:1.378~2.345)、Rsf1高表达(HR=4.282,95%CI:2.682~4.339)是影响患者生存时间的独立危险因素(均P<0.05)。结论CHK2、Rsf1与前列腺癌的发生发展有关,可作为评估前列腺癌患者预后的参考指标。Objective To investigate the changes of Cell Cycle Checkpoint kKinase 2(CHK2),Remodeling and Spacing Factor 1(Rsf1)in prostate cancer tissues and its clinical significance.Methods A total of 121 patients with prostate cancer treated in our hospital from Jan 2016 to Dec 2017 were selected as the observation group,and other 148 patients with benign prostatic hyperplasia treated by surgery during the same period were selected as the control group.The expression of CHK2 RSF1 in benign hyperplasia of prostate cancer was detected by immunohistochemistry.Results The proportion of CHK2 low expression and Rsf1 high expression in the observation group was significantly higher than that in the control group(P<0.001).The proportion of CHK2 low expression and Rsf1 high expression in patients with PSA≤20 ug/L was significantly higher than that in patients with PSA≤20 ug/L.The proportion of CHK2 low expression and Rsf1 high expression in patients with stage III-IV was significantly higher than that in patients with stage I-II.The proportion of CHK2 low expression and Rsf1 high expression in patients with Gleason score≥8 was significantly higher than that in patients with Gleason score<8.The proportion of CHK2 low expression and Rsf1 high expression in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis(P<0.05).The 3-year overall survival rate of patients with high CHK2 expression(56.52%)was lower than that of patients with low CHK2 expression(77.55%),and the overall survival rate of patients with high Rsf1 expression(82.35%)was higher than that of patients with low Rsf1 expression(62.26%)(P<0.05).Gleason score≥8(HR=2.735,95%CI:1.582~3.953),lymph node metastasis(HR=1.942,95%CI:1.492~3.285),low expression of CHK2(HR=1.628,95%CI:1.378~2.345),and high expression of Rsf1(HR=4.282,95%CI:2.682~4.339)were independent risk factors affecting the survival time of patients(all P<0.05).Conclusion CHK2,Rsf1 are related to the occurrence and development of prostate cancer an

关 键 词：前列腺癌 生物标志物 免疫组化 

分 类 号：R737.25[医药卫生—肿瘤]